Nanjing Leads Biolabs Co., Ltd. operates as a pharmaceutical company. It engages in the research, development and commercialization of novel antibody drugs. The firm is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of innovative therapies, focusing on addressing diseases that cannot be treated by existing therapies represented by PD-1/PD-L1 antibodies, in order to meet the unmet medical needs in China and around the world in tumors, autoimmune diseases and other major diseases. The company was founded by Xiao Qiang Kang and Shou Peng Lai on November 27, 2012 and is headquartered in Nanjing, China.